Tweet épinglé
📣We just published final results of our CHEERS trial @JAMAOnc investigating the combination of subtotal subablative SBRT ☢️ with anti-PD-(L)1 monotherapy 💉 in pts with advanced solid tumors ja.ma/3pBquxM
English
Mathieu Spaas
15 posts
Absolutely, some more insight into overall disease burden is provided in the online supplements 🔎
Nicholas Zaorsky, MD MS@NicholasZaorsky
@MathieuSpaas @JAMAOnc Also, consider disease volume and velocity. If these are high, any therapy may have limited benefit. pubmed.ncbi.nlm.nih.gov/33599706/ If 7/45 pts had progression pre treatment, >2/3 were >1st line systemic tx, 50% had progression at 3 mos follow-up, it is likely a high risk cohort.
English
@gv_lazcano @JAMAOnc Similar to PEMBRO-RT and @seanmmcbride we hypothesized that higher SBRT doses might abrogate a potential immune stimulatory effect, based on preclinical data by @CVanpouilleBox
English
@MathieuSpaas @JAMAOnc Is there a reasoning for the used SBRT dose when higher doses are used in similar contexts? (Can't access full paper with my institutional proxy)
English
📣We just published final results of our CHEERS trial @JAMAOnc investigating the combination of subtotal subablative SBRT ☢️ with anti-PD-(L)1 monotherapy 💉 in pts with advanced solid tumors ja.ma/3pBquxM
English
✅Conclusion: while safe, adding subablative multisite SBRT to anti-PD-(L)1 monotherapy did not result in a clinically meaningful benefit
🙏 Thank you to pts, families, trial staff and investigators for participating in this @komop_tgkanker and @VarianMedSys sponsored trial!
English
👥 >2/3 polyM+ pts and >1st line systemic Tx
😷 7/45 pts did not complete SBRT due to early PD or intercurrent illness
☢️ SBRT treated lesions were mostly 🫁 mets and lymph nodes
English
This phase 2 RCT recruited n=99 with advanced melanoma, RCC, UC, HNSCC and NSCLC across 5 Belgian 🇧🇪 hospitals between 2018-2020
➡️ Randomized 1:1 between 💉anti-PD-(L)1 alone or in combination with ☢️ SBRT 3x8Gy of up to 3 tumor lesions
English
Mathieu Spaas retweeté
Words of wisdom on the NIVES trial: SBRT + nivo in mRCC. Our take on what is next and abandon the quest for the "abscopal" effect. @MathieuSpaas @NoraSundahl @_ShankarSiva @rweichselbaum
bit.ly/3oOQXDq
English
Mathieu Spaas retweeté
Really pleased to bring this to fruition. Collaboration between multiple partners to shed insights on combination immunotherapy and radiotherapy, so as to guide best combination therapies! #RTimmuno #checkpoint blockade #precisionRT @ASTRO_org redjournal.org/article/S0360-…
English
Mathieu Spaas retweeté
Review: Characterisation & classification of #oligometastatic disease: a @ESTRO_RT and @EORTC consensus recommendation thelancet.com/journals/lanon…
English
@ReneeBultijnck @piet_ost @AustProstate @hagsie @NoraSundahl @EliseDeBleser @AurelieBruycker Seconded!
English
@piet_ost @AustProstate @hagsie Your're the best supervisor a PhD student could wish for! 🤗#phdlife Think others will agree on that @NoraSundahl @MathieuSpaas @EliseDeBleser @AurelieBruycker 😀
English
When you think to travel light to @AustProstate #apcc19 but your PhD student @ReneeBultijnck asks you to bring “some” stuff for her research stay with @hagsie...
English
Mathieu Spaas retweeté
Great news. Let's include as many as possible in the CHEERS trial when starting anti PD(L)-1. Maybe we can further improve the outcome! @JulesBordet #OncoAlert
Philippe Aftimos, MD @aftimosp
#OncoAlert #ImmunoOnc Nivolumab treatment was associated with long-term survival in a subset of heavily pretreated patients with advanced melanoma, RCC, or NSCLC ja.ma/2TeMn10
English